Benzinga's M&A Chatter for Wednesday August 21, 2013
The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday August 21, 2013:
Report Onyx Provides Drug Trial Data to Potential Bidders
Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) surged higher after-hours on a report from Reuters that the company has given potential buyers, including Amgen (NASDAQ: AMGN), access to trial data. Talks between Onyx and Amgen reportedly hit a snag last week on a dispute over trial data about the blood cancer drug Kyprolis.
Onyx Pharmaceuticals closed at $116.59 Wednesday, but rose above $120 per share in the after-hours session.
IDEXX Laboratories Acquires Brazil Distributor Madasa do Brasil
IDEXX Laboratories (NASDAQ: IDXX) announced Wednesday that it has acquired all outstanding shares of Madasa do Brasil Ltda., a distributor of IDEXX Dairy and bovine testing products based in Sao Paulo, Brazil. All Madasa employees will join IDEXX and continue to operate in Sao Paulo.
IDEXX Laboratories closed at $95.87 Wednesday, a loss of $0.64.
Analyst Sees Potential SodaStream Buyout
The Analyst Note:
Longbow Research initiated SodaStream (NASDAQ: SODA) with a Buy rating on Wednesday, saying they believed "a future partnership with major soda makers or a full buyout seems likely within the next 36 months." In June, it was reported by Calcalist that PepsiCo (NYSE: PEP) was in talks to buy SodaStream, but Pepsi CEO Indra Nooyi denied the rumor.
SodaStream closed at $63.61 Wednesday, a loss of $0.35.
Cenveo to Purchase National Envelope in $25M Cash & Stock Deal
Cenveo (NYSE: CVO) announced Wednesday that will acquire substantially all of the operating assets of National Envelope for approximately $20 million in cash and $5 million in Cenveo common stock. In conjunction with Cenveo's agreement, Hilco Receivables will acquire substantially all the accounts receivable and Southern Paper will purchase the inventory of the Company.
Cenveo closed at $2.73 Wednesday, a gain of almost 4%.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.